Amarin (AMRN) Shows Early Strength Following Vascepa Phase 3 Update
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Down)
Trade AMRN Now!
Shares of Amarin Corp (Nasdaq: AMRN) are indicated for a stronger open Wednesday, following late Tuesday news about publication of new data from its pivotal MARINE Phase 3 clinical trial.
In the release, Amarin noted, "This publication reported that Vascepa significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles."
Shares are up nearly 2 percent ahead of the bell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
In the release, Amarin noted, "This publication reported that Vascepa significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles."
Shares are up nearly 2 percent ahead of the bell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- Highway Holdings (HIHO) Halted Again on Circuit Breaker; Last Up 80%
- Miners (GDX) on Watch with Barrick Gold (ABX), Silver Wheaton (SLW) Both Halted
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
